NMDA수용체길항제로작용하는4-(말단치환-알콕시)-퀴놀린-2-카복실산유도체
    37.
    发明授权
    NMDA수용체길항제로작용하는4-(말단치환-알콕시)-퀴놀린-2-카복실산유도체 失效
    作为NMDA受体拮抗剂的4-(末端烷基) - 喹啉-2-羧酸衍生物

    公开(公告)号:KR100274171B1

    公开(公告)日:2000-12-15

    申请号:KR1019970078811

    申请日:1997-12-30

    Abstract: PURPOSE: Provided are the novel NMDA receptor antagonists, 4-(end-substituted-alkoxy)-quinoline-2-carboxylic acid derivatives and the preparation method thereof. CONSTITUTION: The novel derivatives are represented as shown in the chemical formula 1, where n is 0¯3, Nu are appropriately substituted arylthio, heterocyclicthio, alkylphoshponate, arylsulfonyl, phthalimide, alkylthio, aralkylthio, carbocyclic thio, non-aromatic thio, arylphosphonate, C3¯C7 heterocyclo alkyl, C3¯C7 heterocyclo alkyl(C1¯C6)alkyl, hetero aryl, hetero aryl(C1¯C6)alkyl heterocycle, C1¯C20 alkyl, C6¯ C12 aryl, cyano, hydroxyl, halogen or alkylsufonyl groups. The synthetic process comprises the steps of: alkylating 5,7-dichlorokynurenic acid methylester with α,ω -dibromoalkane; substituting the bromine with nucleophilic groups and hydrolysing with bases to make the compound of formula 1. When Nu is sulfonyl group, preparation method consists of two more steps of oxidizing the sulfide group of Nu in the chemical formula 1 with m-CPBA and hydrolysing the resultant with aqueous sodium hydroxide. They are strong and unique antagonists acting on the coupling position of the strychnine non-susceptive glycine in the NMDA receptor complex and penetrate effectively into central nervous system. Their tautomer, isomer and pharmaceutically acceptable salts are effective treatment and/or preventive drugs for the neurodegeneration and are specially useful for the CNS damage effected by the diseases such as heart attack, low blood sugar, local anemia and heart beat halt, arising from the low oxygen concentration caused by the external wounds or anemia. For the treatment of neurodegeneration, 0.05¯5.0mg/kg dosages are injected intravenously.

    Abstract translation: 目的:提供新型NMDA受体拮抗剂4-(末端取代 - 烷氧基) - 喹啉-2-羧酸衍生物及其制备方法。 构成:新型衍生物如化学式1所示,其中n为0〜3,Nu为适当取代的芳硫基,杂环硫基,烷基磷酸酯,芳基磺酰基,邻苯二甲酰亚胺,烷硫基,芳烷硫基,碳环硫基,非芳族硫基,芳基膦酸酯, C 3 -C 7杂环烷基,C 3 -C 7杂环烷基(C 1 -C 6)烷基,杂芳基,杂芳基(C 1 -C 6)烷基杂环,C 1 -C 20烷基,C 6 -C 12芳基,氰基,羟基,卤素或烷基磺酰基。 合成方法包括以下步骤:用α,ω-二溴烷烃将5,7-二氯喹诺酮酸甲酯烷基化; 用亲核基团取代溴并用碱水解制备式1的化合物。当Nu为磺酰基时,制备方法由化学式1中的Nu的硫化物基团与m-CPBA氧化两个步骤,并水解 与氢氧化钠水溶液混合。 它们是强力和独特的拮抗剂,作用于NMDA受体复合物中士的宁非感受性甘氨酸的偶联位置,并有效渗入中枢神经系统。 它们的互变异构体,异构体和药学上可接受的盐是用于神经变性的有效治疗和/或预防药物,并且特别适用于由诸如心脏病发作,低血糖,局部贫血和心跳停止等疾病影响的CNS损伤 由外部伤口或贫血造成的低氧浓度。 为了治疗神经变性,静脉注射0.05〜5.0mg / kg剂量。

    NMDA 수용체 길항제로 작용하는 4-치환-퀴놀린-2-카복실산 유도체
    38.
    发明授权
    NMDA 수용체 길항제로 작용하는 4-치환-퀴놀린-2-카복실산 유도체 失效
    作为NMDA受体拮抗剂的4-取代的喹啉-2-羧酸衍生物

    公开(公告)号:KR100267707B1

    公开(公告)日:2000-10-16

    申请号:KR1019980006275

    申请日:1998-02-26

    Abstract: PURPOSE: Provided is 4-substituted-quinoline-2-carboxylic acid derivative which acts as an antagonist of NMDA receptor. And its pharmaceutically acceptable salt is provided. CONSTITUTION: 4-substituted-quinoline-2-carboxylic acid derivative is represented from the formula (1), wherein R1 can be sulfonamide, amide or alkylthio, (3-(4-benzyl-piperazine-1-yl)-propyl)-(toluene-4-sulfonyl)-amino group or (2-(4-benzyl-piperazin-1-yl)-ethyl)-(toluene-4-sulfonyl)-amino group.

    Abstract translation: 目的:提供作为NMDA受体拮抗剂的4-取代喹啉-2-羧酸衍生物。 并提供其药学上可接受的盐。 组成:4-取代 - 喹啉-2-羧酸衍生物由式(1)表示,其中R 1可以是磺酰胺,酰胺或烷硫基,(3-(4-苄基 - 哌嗪-1-基) - 丙基) - (甲苯-4-磺酰基) - 氨基或(2-(4-苄基 - 哌嗪-1-基) - 乙基) - (甲苯-4-磺酰基) - 氨基。

    히드로벤조아제핀 및 히드로벤조아조신 유도체의 제조방법
    39.
    发明公开
    히드로벤조아제핀 및 히드로벤조아조신 유도체의 제조방법 失效
    制备氢苯并吖庚因和氢化苯并偶氮辛衍生物的方法

    公开(公告)号:KR1019980083463A

    公开(公告)日:1998-12-05

    申请号:KR1019970018772

    申请日:1997-05-15

    Abstract: 본 발명은 하기 화학식 1로 표시되는 히드로벤조아제핀 및 히드로벤조아조신 유도체의 제조방법에 관한 것으로서, 본 발명의 제조방법에 의하면 바닐로이드 (Vanilloid) 수용체의 항진제인 캡사제핀 (Capsazepine) 합성을 비롯하여 생물학적 활성을 지닌 많은 천연물을 합성하는데 중요한 중간체인 히드로벤조아제핀 및 히드로벤조아조신 유도체를 짧은 반응단계로 수율 높게 제조할 수 있다.
    [화학식 1]

    상기식에서, X 및 Y 는 같거나 다를 수 있으며, 히드록시이거나 메톡시이고, n 은 1 내지 4 의 정수이며, R 은 H, CO
    2 CH
    2 Ph, COPh, CH
    2 Ph 또는 CHPh
    2 이다.

    테트라하이드로벤조티오펜 유도체, 이의 제조방법 및 이를 함유하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물
    40.
    发明授权
    테트라하이드로벤조티오펜 유도체, 이의 제조방법 및 이를 함유하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물 有权
    四氢苯并噻吩衍生物,其制备方法以及用于预防或治疗含有其的病毒性疾病的药物组合物

    公开(公告)号:KR101773575B1

    公开(公告)日:2017-08-31

    申请号:KR1020150110250

    申请日:2015-08-04

    CPC classification number: Y02A50/463 Y02A50/465

    Abstract: 본발명은테트라하이드로벤조티오펜유도체, 이의약학적으로허용가능한염 또는이의광학이성질체, 이의제조방법및 이를유효성분으로함유하는바이러스성질환의예방또는치료용약학적조성물에관한것이다. 본발명에따른테트라하이드로벤조티오펜유도체는피코르나바이러스군에속하는콕사키바이러스, 폴리오바이러스및 라이노바이러스에대하여우수한항바이러스활성을나타내므로바이러스성질환의예방또는치료용약학적조성물로유용하게사용될수 있다.

    Abstract translation: 本发明涉及一种四氢苯并噻吩衍生物,其药学上可接受的盐或该方法的用于在含有它们作为有效成分的病毒疾病预防或治疗的物质及其制备方法和药物组合物的光学异构体。 四氢苯并噻吩衍生物的血液胸衣或者手足口病毒属于病毒组,脊髓灰质炎病毒和附接根据本发明的表现出针对病毒优异的抗病毒活性可用作病毒性疾病的预防或治疗药物的医药组合物 它可以是。

Patent Agency Ranking